Cancer Network spoke with Daniel George, MD, of Duke Health, about the treatment landscape and current trials for renal cell carcinoma.
Daniel George, MD
Advertisement
Articles by Daniel George, MD
In this video, Dr. Daniel George discusses CARMENA, which asked if cytoreductive surgery is necessary in the age of active systemic therapy for mRCC.
Advertisement
Latest Updated Articles
Can mRCC Patients Be Spared Debulking Nephrectomy?Published: June 12th 2018 | Updated:
Dr. Daniel George on the Treatment Landscape for RCCPublished: June 11th 2019 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
3
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
4
FDA Approves Revumenib in R/R NPM1-Mutant AML
5
